The Business Development & Strategy Team at Fred Hutch has a stellar track record of finding partners who share our drive to innovate, collaborate and accelerate the development of high-impact technologies and therapies. The result has been dozens of licensing agreements, strategic partnerships, spinouts and startups, including such high-profile launches as Juno Therapeutics, Adaptive Biotechnologies, Nohla Therapeutics and Faraday Pharmaceuticals.
The pioneering immunotherapy company Juno Therapeutics was founded in 2013 as a partnership between Fred Hutch, Memorial Sloan-Kettering Cancer Research Center and Seattle Children’s Research Institute, licensing cutting-edge research from all three institutions. It launched with $120 million in private investment funding, making it one of the largest biotech startups in history. Juno initially targeted blood cancers but has expanded its focus to include some solid-tumor cancers, such as colorectal cancer and certain sarcomas, in further partnership with Fred Hutch investigators.
We provide state-of-the-art data infrastructure and data science support for our investigators in areas such as data mining, machine learning, mobile app development and bioinformatics.Learn More
We maintain our own 37,000-square-foot facility that produces high-quality stem cell products for research, clinical trials and therapeutic use.
Fred Hutch researchers are eligible to apply for special funding to help them take their discoveries and ideas to a commercially viable stage.